STOCK TITAN

EXELIXIS (EXEL) SEC Filings, Apr-May 2026

EXEL NASDAQ

Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.

Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.

Rhea-AI Summary

EXELIXIS, INC. director Maria C. Freire reported an exercise-and-sale transaction in company stock. On May 7, 2026, she exercised options to acquire 20,634 shares of Common Stock at $19.77 per share, then sold 20,634 shares in an open-market sale at $46.00 per share.

After these transactions, she directly holds 100,819 shares of Common Stock, which include 9,812 shares that will be issued upon vesting of restricted stock units. The option exercised covered 20,634 shares, became fully exercisable on May 23, 2019, and now has no remaining balance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
insider
-
Rhea-AI Summary

EXELIXIS, INC. director George Poste reported an open-market sale of 60,000 shares of common stock on May 7, 2026 at a weighted average price of $45.71 per share. The transactions were executed in multiple trades between $45.65 and $45.85 per share.

Following the sale, Poste directly holds 118,832 shares of Exelixis common stock, which includes 9,812 shares that will be issued upon vesting of restricted stock units (RSUs). Each RSU represents the economic equivalent of one share of common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
insider
-
Rhea-AI Summary

EXELIXIS, INC. President and CEO Michael Morrissey reported a charitable stock transfer and updated holdings. On May 6, 2026, he made a bona fide gift of 109,676 shares of Exelixis common stock to the Bombora Rise Foundation through the Morrissey Family Living Trust, which then held 1,880,280 shares indirectly. He is also shown with 1,614,552 shares of common stock that will be issued upon vesting of restricted stock units and performance-based awards, plus 17,728 shares held through the Exelixis 401(k) Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
insider
Rhea-AI Summary

Mary Beckerle, a director of Exelixis, Inc. (EXEL), listed 7,712 common shares for sale, with an aggregate market value of $373,646.40. The notice gives an approximate sale date of May 7, 2026, and names Morgan Stanley Smith Barney LLC as the broker. The listed shares include 3,856 shares from restricted stock vesting on January 5, 2026, and 3,856 shares from an option exercise on May 7, 2026; both acquisitions were under registered plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
other
-
Rhea-AI Summary

EXEL reported a notice of proposed sale of securities: the filing lists a proposed sale of 60,000 shares of Common Stock and an aggregate amount of $2,742,468.00, with 251,355,083 shares shown on the same line and the date 05/07/2026. The schedule itemizes multiple tranches of restricted stock vesting under a registered plan with specific vesting dates and share counts (examples: 3,457; 3,458; 15,538). The notice is a routine Form 144 disclosure by an affiliate identifying securities to be sold under a registered plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
other
-
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
other
Rhea-AI Summary

Exelixis, Inc. reported strong first‑quarter 2026 growth, driven mainly by its cabozantinib franchise. Total revenues rose to $610.8 million from $555.4 million a year earlier, with net product revenues increasing to $555.0 million. Net income climbed to $210.5 million, up from $159.6 million, and diluted EPS improved to $0.79 from $0.55, reflecting operating leverage as total operating expenses stayed roughly flat.

The company ended the quarter with $1.43 billion in cash, cash equivalents and marketable securities and continued returning capital to shareholders, repurchasing common stock for $430.4 million of cash in the quarter as part of a broader buyback program. Exelixis also highlighted progress in its oncology pipeline, including zanzalintinib, which has an FDA‑accepted New Drug Application in metastatic colorectal cancer and multiple ongoing pivotal and phase 2 studies across several tumor types.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.64%
Tags
quarterly report
-
Rhea-AI Summary

Exelixis reported strong first quarter 2026 results and expanded its stock repurchase plans. Total revenues were $610.8 million, up from $555.4 million a year earlier, driven by net product revenues of $555.0 million, largely from the U.S. cabozantinib franchise. GAAP net income was $210.5 million, or $0.79 per diluted share, while non-GAAP diluted EPS was $0.87.

The company reaffirmed 2026 guidance, including total revenues of $2.525–$2.625 billion and net product revenues of $2.325–$2.425 billion, with an effective tax rate of 21–23%. Exelixis’ board authorized a new $750 million stock repurchase program through December 31, 2027, after repurchasing $590.6 million under its October 2025 program and $2.59 billion cumulatively since March 2023, retiring 86.8 million shares.

Pipeline momentum continued as the FDA accepted the NDA for zanzalintinib in previously treated metastatic colorectal cancer, with a PDUFA target action date of December 3, 2026. Multiple pivotal trials, including STELLAR-303, STELLAR-304, STELLAR-311, STELLAR-316 and Merck’s LITESPARK-033 and -034, are underway or planned across colorectal, renal cell, neuroendocrine and other tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.64%
Tags
current report
-
Rhea-AI Summary

Exelixis Inc Schedule 13G shows Vanguard Capital Management reported beneficial ownership of 13,233,247 shares of common stock, representing 5.09% of the class. The filing states Vanguard has sole dispositive power over 13,233,247 shares and sole voting power over 1,974,263 shares.

The filing lists Vanguard affiliates and clarifies holdings include shares held for funds and managed accounts. The form is signed by Vanguard's Head of Global Fund Administration on 04/29/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
ownership
Rhea-AI Summary

Exelixis, Inc. calls a virtual 2026 Annual Meeting on May 26, 2026, asking stockholders to elect eleven directors, ratify Ernst & Young LLP as auditor, approve a 2,000,000‑share increase to the 2017 Equity Incentive Plan, and give an advisory Say‑on‑Pay vote.

The company highlights 2025 as its ninth consecutive year of operating profitability, with total revenue of $2.32 billion, up 7% year over year, driven by the cabozantinib franchise. Exelixis filed its first New Drug Application for zanzalintinib, accepted for FDA review in early 2026, and continued pivotal trials.

Management emphasizes disciplined capital allocation, including share repurchases, and a one‑time broad‑based equity grant to reinforce ownership culture and retention. The proxy details board composition, committee structure, director independence, and extensive governance, risk oversight and compensation frameworks aligned to long‑term oncology growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
proxy

FAQ

How many EXELIXIS (EXEL) SEC filings are available on StockTitan?

StockTitan tracks 102 SEC filings for EXELIXIS (EXEL), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for EXELIXIS (EXEL)?

The most recent SEC filing for EXELIXIS (EXEL) was filed on November 9, 2026.